A ten-week, multicenter, randomized, double-blind, placebo and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety, and tolerability of GSK372475 [NS 2359] (1.5 mg/day to 2.0 mg/day) or extended release venlafaxine XR (150 mg/day to 225 mg/day) compared to placebo in adult subjects diagnosed with major depressive disorder.

Trial Profile

A ten-week, multicenter, randomized, double-blind, placebo and active-controlled, parallel-group, flexible-dose study evaluating the efficacy, safety, and tolerability of GSK372475 [NS 2359] (1.5 mg/day to 2.0 mg/day) or extended release venlafaxine XR (150 mg/day to 225 mg/day) compared to placebo in adult subjects diagnosed with major depressive disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs NS 2359 (Primary) ; Venlafaxine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 May 2012 Results published in the Journal of Psychopharmacology.
    • 10 Dec 2009 Results presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology.
    • 01 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top